Launching of new prescription pain treatment to be delayed
Published: 2008-07-23 06:56:00
Updated: 2008-07-23 06:56:00
Janssen Korea says Jurnista prolonged-release tablets (hydromorphone HCl), a new prescription treatment for severe pain, will not be available on market in September, as its price negotiation with the National Health Insurance Corp. failed.
The assessment is likely to take time since Janssen K...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
